Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer (MWA in NSCLC)


Shandong First Medical University

Status and phase

Phase 2




Other: Camrelizumab plus microwave ablation
Drug: Camrelizumab

Study type


Funder types



Shandong PH

Details and patient eligibility


Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.

Full description

Patients in the camrelizumab group were treated with camrelizumab with the dose of 200mg on day 1, repeated every 21 days.Patients in the combination group were treated with MWA in the primary tumor followed by camrelizumab with the dose of 200mg on day 1, repeated every 21 days. The primary end point is overall survival. The second end points include progression free survival, objective response rate and safety.


200 estimated patients




18 to 80 years old


No Healthy Volunteers

Inclusion criteria

  • Aged 18 to 75 years old
  • Cytologically or pathologically verified non-small cell lung cancer (NSCLC)
  • Patients with distant metastases or postoperative recurrence
  • EGFR or ALK sensitive mutations are negative (all patients, including non-adenocarcinoma patients)
  • At least one line of platinum-based doublet chemotherapy was administrated
  • Eastern Cancer Cooperative Group(ECOG)Performance Status(PS)of 0 to 1
  • At least two measurable tumors (in other words a measurable tumor lesion exclusive primary tumors)
  • Asymptomatic brain metastases or symptomatic brain metastases under control
  • If treated with irradiation,at least one month interval between radiation and randomization 10)Cardiopulmonary function, laboratory test indicators without ablation or chemotherapy contraindications

11) Informed conssent can be obtained 12) Sufficient tissue specimens for PD-L1 or TMB or blood samples were provided (1 week before treatment, 1 week after ablation, and once every two months for immune evaluation) for subsequent analysis

Exclusion criteria

  • Mixed lung cancer contains neuroendocrine tumor, small cell lung cancer or sarcoma
  • Suffering from other malignant tumors within five years
  • EGFR, ALK sensitive mutations are positive or unknown
  • ECOG PS≥2
  • Uncontrolled pleural effusion or pericardial effusion
  • Uncontrolled symptomatic brain metastases
  • Previously anti-PD-1, anti-PD-L1, anti-CTLA-4 or Car-T immunotherapy
  • severe interstitial pneumonia with severe diffuse dysfunction
  • Autoimmune diseases require long-term hormone therapy patients
  • Patients required consistent application of prednisone
  • Uncontrolled pulmonary infection or antibiotics stopped within 1 month
  • Acute cardiovascular and cerebrovascular diseases such as acute cerebral infarction and acute coronary syndrome within 1 month
  • Patients during pregnancy or lactation
  • Life expectance of 3 months or less

Trial design

200 participants in 2 patient groups, including a placebo group

Microwave ablation plus camrelizumab group
Active Comparator group
Patients in the group are treated with Microwave ablation in the primary tumor, followed by camrelizumab.
Other: Camrelizumab plus microwave ablation
Camrelizumab group
Placebo Comparator group
Patients in the group are treated with camrelizumab alone.
Drug: Camrelizumab

Trial contacts and locations



Central trial contact

Xin Ye; Zhigang Wei

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems